Biotech Values

[DewDiligence]

MNTA TEVA SNY re Lovenox patent:

Sanofi has asked the US Supreme Court to review the ruling of patent invalidity based on inequitable conduct. Sanofi has nothing to lose by trying; however, reversing the lower court’s ruling, which has been sustained by the appellate court, is a very long longshot, IMO.

http://ip.law360.com/registrations/user_registration?article_id=85156

Even if the Supreme Court should decide to take the case, it would not stop the 180-day exclusivity clock for Amphastar (#msg-35170055).